Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Accounts Payables (2016 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Accounts Payables for 14 consecutive years, with $4.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accounts Payables fell 21.62% year-over-year to $4.0 million, compared with a TTM value of $4.0 million through Dec 2025, down 21.62%, and an annual FY2025 reading of $4.0 million, down 21.62% over the prior year.
  • Accounts Payables was $4.0 million for Q4 2025 at Karyopharm Therapeutics, down from $5.4 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $9.0 million in Q1 2023 and bottomed at $813000.0 in Q3 2022.
  • Average Accounts Payables over 5 years is $3.4 million, with a median of $2.9 million recorded in 2021.
  • The sharpest move saw Accounts Payables tumbled 63.98% in 2021, then soared 513.26% in 2024.
  • Year by year, Accounts Payables stood at $1.6 million in 2021, then surged by 72.99% to $2.8 million in 2022, then rose by 12.62% to $3.1 million in 2023, then surged by 63.53% to $5.1 million in 2024, then fell by 21.62% to $4.0 million in 2025.
  • Business Quant data shows Accounts Payables for KPTI at $4.0 million in Q4 2025, $5.4 million in Q3 2025, and $2.6 million in Q2 2025.